IMVAMUNE®: Modified vaccinia Ankara strain as an attenuated smallpox vaccine

Immunology and Microbiology

• Smallpox Vaccine 100%
• Modified Vaccinia Ankara 100%
• Atopic Dermatitis 28%
• Immune Response 28%
• Immunodeficiency 14%
• Cell Line 14%
• Solution and Solubility 14%
• Human Immunodeficiency Virus 14%
• Vaccinia Virus 14%
• High Risk Population 14%
• Homo sapiens 14%
• Replication 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Smallpox Vaccine 100%
• Modified Vaccinia Ankara 100%
• Adverse Event 28%
• Atopic Dermatitis 28%
• HIV 14%
• Clinical Trial 14%
• Immune Deficiency 14%
• Vaccinia Virus 14%
• Homo sapiens 14%